Toceranib

Toceranib is a medication used to treat certain types of cancer in dogs. It is used to treat mast cell tumors, a type of cancer that affects the skin and other organs. Toceranib is a tyrosine kinase inhibitor, which means it works by blocking enzymes that are involved in the growth of cancer cells. It is usually given once daily as a pill or capsule. Common side effects include vomiting, diarrhea, loss of appetite, and weight loss.

Toceranib, sold under the brand name Palladia, is a medication used to treat a specific type of cancer in dogs. Here's a detailed breakdown of its function and use in veterinary medicine:

Function: Toceranib is a receptor tyrosine kinase inhibitor (RTKI) [1, 2]. This means it targets and blocks specific enzymes called tyrosine kinases on cancer cells. These enzymes play a crucial role in promoting cancer cell growth and survival. By inhibiting these enzymes, Toceranib helps to slow or stop the growth of cancer cells.

Medical Use in Dogs:

  • Toceranib is specifically approved for the treatment of mast cell tumors in dogs [1, 3]. Mast cell tumors are a type of cancer that can develop from mast cells, which are immune system cells found in various tissues throughout the body.

How it's Administered:

  • Toceranib comes in tablet form and is typically given to dogs orally, once daily, with or without food [3].

Benefits:

  • Toceranib can be an effective treatment option for dogs with mast cell tumors, especially those that have spread (metastasized) or haven't responded well to other therapies [2].

Important Considerations:

  • Toceranib can cause side effects in dogs, including vomiting, diarrhea, loss of appetite, lethargy, and skin problems [3].
  • It's crucial to monitor your dog closely for any side effects and discuss them with your veterinarian.
  • Toceranib may not be suitable for all dogs, particularly those with underlying health conditions or pregnant or lactating dogs [3].
  • Regular veterinary checkups are necessary while your dog is on Toceranib to monitor their response to the medication and overall health.
Anatomical Therapeutic Chemical Classification
QL - Antineoplastic and immunomodulating agents
QL01 Antineoplastic agents
QL01E - Protein kinase inhibitors
QL01EX Other protein kinase inhibitors
External Links